New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

— ClearFlow Executives Comment on Need for New Protocols —  Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have drainage catheters to remove shed blood from around the heart and lungs in the early hours of recovery following surgery.  Evidence suggests that these drainage catheters, or chest tubes, have a high failure rate due to clogging, leading to what is known as Retained Blood

Active Clearance of Chest Tubes Reduces Bleeding Complications After Left Ventricular Assist Device Implantation for Heart Failure

ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) was published in the November/December 2016 edition of the American Society of Artificial Internal Organs (ASAIO) Journal (Vol. 62, Issue 66, p. 704-709). Data from the peer-reviewed paper, titled “Active Clearance of Chest Tubes Reduces Re-exploration for Bleeding After Ventricular Assist Device Implantation”

ClearFlow Opens New Distribution Center to Service European Market

Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or minimizes chest tube clogging. A chest tube that is occluded can lead to retained blood around the heart and lungs, which in turn leads to an increase in likelihood of complications and extended hospital stays. The PleuraFlow System is approved for use in the U.S., Europe, Australia, Brazil, and Canada, and has either cleared or

Clinical and Economic Benefits of Maintaining Chest Tube Patency Discussed at Cardiovascular-Thoracic (CVT) Critical Care Conference

ClearFlow Participates in Clinical Panel Presentations at Critical Care Conference Washington, DC – September 20, 2016—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the clinical and economic benefits of maintaining chest tube patency following cardiothoracic surgery last Friday at a session sponsored during the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac surgery intensive care leaders from around the world gathered at the conference, organized by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) in Washington, DC. CVT Critical Care Conference is one of the premier settings for cardiac critical care exchange of ideas. Specialists

ClearFlow Launches FDA-Cleared PleuraFlow System for Pediatric Cardiothoracic Surgery

Anaheim, CA – July 26, 2016 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that its PleuraFlow® Active Clearance Technology® is now available for the treatment of pediatric cardiothoracic surgery patients.  After receiving clearance from the United States Food & Drug Administration (FDA) earlier this year for expanded Indications for Use with the company’s patented technology, ClearFlow developed a new model of the PleuraFlow product for the pediatric market. All patients undergoing heart surgery have some degree of bleeding, and thus, all patients require chest tubes to evacuate shed blood from around the heart and lungs in the early hours after surgery. The problem is